MarketCap
Facebook
X
TelegramQuarterly report 2022-Q4
added 01-26-2023
Myovant Sciences Ltd. Total Shareholders Equity 2011-2026 | MYOV
Annual Total Shareholders Equity Myovant Sciences Ltd.
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -354 M | -108 M | 4.33 M | 37.7 M | 167 M | -223 K | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 167 M | -354 M | -42.3 M |
Quarterly Total Shareholders Equity Myovant Sciences Ltd.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -558 M | -513 M | -484 M | -473 M | -432 M | -383 M | -400 M | -400 M | -271 M | -271 M | -200 M | -135 M | -48.9 M | -48.9 M | 17.3 M | 79.6 M | 46.7 M | 46.7 M | 74.1 M | 37.7 M | 82.2 M | 119 M | 146 M | 167 M | 186 M | -37.9 M | - | -223 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 186 M | -558 M | -135 M |
Total Shareholders Equity of other stocks in the Biotechnology industry
| Issuer | Total Shareholders Equity | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acorda Therapeutics
ACOR
|
-158 M | - | -24.86 % | $ 820 K |  USA |
 |
Adverum Biotechnologies
ADVM
|
70.7 M | - | - | $ 86.2 M | USA |
 |
MorphoSys AG
MOR
|
621 M | - | 2.43 % | $ 254 M |  Germany |
 |
Akari Therapeutics, Plc
AKTX
|
28.3 M | $ 5.12 | 11.55 % | $ 345 B |  Britain |
 |
Alterity Therapeutics Limited
ATHE
|
35.5 M | $ 3.97 | 6.43 % | $ 9.55 B |  Australia |
 |
Akouos
AKUS
|
234 M | - | 0.23 % | $ 488 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
789 M | $ 320.13 | -3.98 % | $ 41.9 B | USA |
 |
Applied Molecular Transport
AMTI
|
60.8 M | - | - | $ 10.1 M | USA |
 |
I-Mab
IMAB
|
1.72 B | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
78.8 M | - | 4.14 % | $ 49.1 M | USA |
 |
Genfit SA
GNFT
|
-16.2 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
2.27 M | - | -13.47 % | $ 169 M | France |
 |
Aligos Therapeutics
ALGS
|
53.5 M | $ 7.66 | 3.23 % | $ 75.7 M | USA |
 |
Allakos
ALLK
|
169 M | - | - | $ 28.6 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-1.1 M | - | - | $ 7.46 M |  Israel |
 |
Midatech Pharma plc
MTP
|
6.72 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Applied Therapeutics
APLT
|
-17.1 M | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
38.3 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
10.7 M | - | -13.39 % | $ 1.45 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
-9.98 M | - | -2.5 % | $ 5.88 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
789 M | $ 21.81 | 0.6 % | $ 1.02 B | USA |
 |
Burford Capital Limited
BUR
|
1.7 B | $ 4.67 | -1.37 % | $ 766 M | Britain |
 |
CymaBay Therapeutics
CBAY
|
292 M | - | - | $ 3.45 B | USA |
 |
BioNTech SE
BNTX
|
1.37 B | $ 102.12 | 2.66 % | $ 27.2 B | Germany |
 |
Cabaletta Bio
CABA
|
112 M | $ 3.52 | 3.53 % | $ 354 M | USA |
 |
Advaxis
ADXS
|
-24.4 M | - | -9.65 % | $ 45.9 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
5.59 M | $ 3.08 | -4.94 % | $ 5.07 M | Israel |
 |
AgeX Therapeutics
AGE
|
-37 K | - | -10.17 % | $ 12.2 K | USA |
 |
ContraFect Corporation
CFRX
|
-11.9 M | - | -5.16 % | $ 5.39 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
715 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
32.6 M | $ 1.35 | -12.9 % | $ 347 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
29.5 M | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
-33.7 M | $ 4.26 | 0.47 % | $ 456 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
189 M | $ 24.19 | -1.59 % | $ 3.08 B | USA |
 |
AIkido Pharma
AIKI
|
69.4 M | - | 1.93 % | $ 17.4 M | USA |
 |
BioDelivery Sciences International
BDSI
|
188 M | - | -4.8 % | $ 255 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
178 M | $ 1.61 | 8.05 % | $ 428 M | Britain |
 |
Aptose Biosciences
APTO
|
-27.2 M | - | -45.71 % | $ 1.2 M |  Canada |
 |
BeiGene, Ltd.
BGNE
|
4.36 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Checkpoint Therapeutics
CKPT
|
-12.6 M | - | - | $ 169 M | USA |
 |
Caladrius Biosciences
CLBS
|
29.6 M | - | -16.75 % | $ 25.8 M | USA |
 |
AVROBIO
AVRO
|
94.7 M | - | 1083.1 % | $ 745 M | USA |
 |
Clearside Biomedical
CLSD
|
-15.9 M | - | - | $ 25.3 M | USA |
 |
Celldex Therapeutics
CLDX
|
527 M | $ 33.86 | -0.03 % | $ 2.25 B | USA |
 |
bluebird bio
BLUE
|
195 M | - | - | $ 546 M | USA |
 |
CNS Pharmaceuticals
CNSP
|
4.52 M | $ 2.75 | - | $ 1.22 M | USA |